Business in Brief - Business - Haaretz.com
Mylan Wins UK Court Ruling Related to Copaxone® 40 mg/mL Patent | Mylan N.V.
High Court Sides With Teva In Patent Dispute
Teva May Move Court Against Dr Reddy's For Patent Infringement | Mint
Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL
EPO destroys Teva copaxone patent after appeal - JUVE Patent
Teva, after locking up new Ajovy patents, sues Eli Lilly again in heated migraine drug fight | Fierce Pharma
Teva's patent failure gives long-acting Copaxone generics free rein | Fierce Pharma
Payers keep squeezing MS drugmakers--and they may just take their tactics elsewhere | Fierce Pharma
Synthon says EPO appeal board has revoked Copaxone API patent
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Rx Item-Copaxone 20Mg/Ml Syringe 30X1 Ml By Teva Pharma Refrigerated
PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Patent Law
Utility Archives - PCK
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Group
Teva loses U.S. patent appeal for 40mg version of Copaxone - Business - Haaretz.com
EPO upholds patent on Copaxone 40mg
Synthon's generic version of Copaxone 40mg approved in Europe
New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis: COBRA study presented at the 7th Congress of the European Academy of Neurology (EAN)
One, two, three, gone: Teva loses third patent on new Copaxone formula | Fierce Pharma
Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents | Business Standard News
With patent strikedown, Teva's new Copaxone formula loses two defenses against generics | Fierce Pharma
Court refuses injunctions in pharma patent case
